Skip to main content

Advertisement

Table 3 Pairwise treatment comparisons from network meta-analyses for the outcomes post-treatment depression scores (above the diagonal) and study discontinuation (below the diagonal)

From: Comparative effectiveness of psychological treatments for depressive disorders in primary care: network meta-analysis

Ftf CBT 0.18 0.21 0.00 0.02 −0.02 −0.16 −0.04 0.06 −1.31 −0.17 0.08 0.05 0.11 −0.02 0.34
−0.09–0.44 −0.07–0.50 −0.66–0.67 −0.21–0.25 −0.25–0.20 −0.88–0.55 −0.31–0.22 −0.20–0.33 −2.15(−0.47) −0.69–0.35 −0.29–0.46 −0.22–0.32 −0.19–0.41 −0.56–0.53 0.160.51
1.47 Ftf PST 0.04 −0.17 −0.16 −0.20 −0.34 −0.22 −0.11 −1.48 −0.35 −0.09 −0.13 −0.06 −0.19 0.16
0.65–3.51 −0.23–0.31 −0.81–0.47 −0.42–0.11 −0.48–0.08 −1.06–0.38 −0.50–0.06 −0.39–0.17 −2.31(−0.66) −0.81–0.12 −0.44–0.25 −0.34–0.09 −0.36–0.24 −0.76–0.37 −0.04–0.36
0.98 0.67 Ftf IPT −0.21 −0.19 −0.24 −0.38–1.11– −0.26 −0.15 −1.52 −0.38 −0.13 −0.16 −0.10 −0.23 0.12
0.30–3.11 0.25–1.70 −0.86–0.44 −0.48–0.09 −0.54–0.06 0.35 −0.56–0.05 −0.45–0.15 −2.36(−0.69) −0.90–0.14 −0.44–0.17 −0.41–0.08 −0.40–0.19 −0.81–0.34 −0.11–0.35
1.72 1.17 1.75 Ftf PDT 0.02 −0.03 −0.17 −0.05 0.06 −1.31 −0.17 0.08 0.05 0.11 −0.02 0,33
0.24–15.2 0.18–9.32 0.25–14.41 −0.65–0.68 −0.70–0.64 −1.11–0.78 −0.72–0.62 −0.61–0.73 −2.31(−0.31) −0.95–0.60 −0.60–0.75 −0.56–0.65 −0.57–0.79 −0.85–0.81 −0,31–0,97
0.99 0.67 1.01 0.58 Ftf Other −0.04 −0.19 −0.06 –0.33– 0.04 −1.33 −0.19 0.06 0.03 0.09 −0.04 0.31
0.48–2.12 0.27–1.59 0.34–3.07 0.07–4.46 −0.30–0.21 −0.90–0.53 0.20 −0.22–0.30 −2.17(−0.49) −0.71–0.33 −0.31–0.43 −0.24–0.30 −0.20–0.39 −0.54–0.46 0.140.49
1.75 1.19 1.79 1.02 1.77 Rtl CBT −0.14 −0.02 0.09 −1.29 −0.15 0.11 0.07 0.14 0.01 0.36
0.67–4.46 0.36–3.51 0.50–6.34 0.09–7.89 0.59–5.14 −0.86–0.58 −0.30–0.26 −0.19–0.36 −2.13(−0.44) −0.68–0.38 −0.28–0.49 −0.21–0.36 −0.18–0.45 −0.55–0.57 0.170.55
0.74 0.51 0.76 0.43 0.75 0.42 Rtl PST 0.12 0.23 −1.14 0.00 0.25 0.22 0.28 0.15 0.50
0.17–3.23 0.11–2.22 0.15–3.32 0.04–4.66 0.18–3.21 0.08–2.17 −0.60–0.84 −0.49–0.95 −2.22(−0.07) −0.86–0.85 −0.52–1.02 −0.51–0.94 −0.46–1.02 −0.72–1.02 −0.19–1.19
0.62 0.42 0.63 0.36 0.63 0.35 0.83 Gsh CBT 0.11 −1.26 −0.13 0.13 0.09 0.16 0.03 0.38
0.24–1.46 0.16–1.00 0.20–1.88 0.04–2.81 0.25–1.56 0.11–1.08 0.19–3.80 −0.17–0.39 −2.11(−0.42) −0.66–0.41 −0.26–0.51 −0.20–0.38 −0.17–0.48 −0.54–0.59 0.180.58
0.66 0.45 0.68 0.39 0.67 0.38 0.89 1.07 Nmc CBT −1.37 −0.23 0.02 −0.01 0.05 −0.08 –0.64– 0.27
0.21–2.08 0.15–1.37 0.19–2.16 0.04–3.48 0.23–1.96 0.102–1.43 0.18–4.43 0.35–3.46 −2.22(−0.53) −0.76–0.30 −0.37–0.40 −0.30–0.2 −0.27–0.37 0.48 0.070.47
No data No data No data No data No data No data No data No data No data Ftf CBT + SSRI 1.14 1.39 1.36 1.42 1.29 1.64
0.212.07 0.542.24 0.562.16 0.572.27 0.312.27 0.822.47
2.04 1.39 2.08 1.19 2.06 1.16 2.74 3.29 3.07 No data Ftf PST + SSRI 0.25 0.22 0.28 0.15 0.50
0.40–9.99 0.34–5.61 0.40–10.65 0.12–12.2 0.40–9.90 0.20–6.44 0.31–20.2 0.65–18.1 0.56–16.7 −0.31–0.81 −0.26–0.70 −0.26–0.82 −0.57–0.88 0.011.00
1.54 1.05 1.58 0.90 1.56 0.88 2.07 2.49 2.32 No data 0.76 Ftf IPT + SSRI −0.03 0.03 −0.10 0.25
0.38–6.64 0.29–4.04 0.50–5.10 0.09–7.19 0.39–6.64 0.18–4.16 0.33–13.7 0.55–10.5 0.48–12.5 0.13–4.68 −0.33–0.27 −0.36–0.42 −0.72–0.53 −0.08–0.58
1.26 0.86 1.29 0.73 1.27 0.72 1.69 2.03 1.90 No data 0.62 0.82 SSRI 0.06 −0.07 0.28
0.52–3.18 0.44–1.76 0.53–3.20 0.11–4.10 0.51–3.45 0.22–2.39 0.39–8.14 0.74–5.83 0.60–6.77 0.16–3.11 0.26–2.73 −0.24–0.37 −0.64–0.50 0.080.49
1.54 1.05 1.58 0.90 1.56 0.88 2.08 2.49 2.33 No data 0.76 1.00 1.23 TCA −0.13 0.22
0.45–5.36 0.37–3.10 0.57–4.37 0.09–7.67 0.50–5.56 0.22–3.54 0.40–11.0 0.70–9.17 0.70–9.57 0.13–4.10 0.23–4.25 0.39–3.90 −0.71–0.45 −0.03–0.48
2.01 1.37 2.06 1.17 2.03 1.15 2.71 3.25 3.04 No data 0.99 1.31 1.60 1.30 Individ.. Antid. 0.35
0.40–9.46 0.25–7.50 0.32–11.74 0.08–12.9 0.46–8.52 0.18–6.73 0.35–19.8 0.57–18.5 0.47–18.4 0.10–9.23 0.17–9.78 0.26–8.45 0.21–8.41 −0.18–0.88
1.00 0.68 1.03 0.59 1.01 0.57 1.35 1.62 1.51 No data 0.49 0.65 0.80 0.65 0.50 UC/placebo
0.57–1.86 0.34–1.27 0.40–2.39 0.08–4.08 0.56–1.86 0.22–1.45 0.36–5.16 0.80–3.24 0.60–3.76 0.11–2.22 0.18–2.33 0.36–1.60 0.21–1.76 0.11–2.48
  1. With regard to post-treatment depression scores, standardized mean differences above 0 favor the row-defining treatment, and below 0 the column-defining treatment. With regard to study discontinuation, odds ratios smaller than 1 favor the column-defining treatment, and odds ratios lower than 1 favor the row-defining treatment. Reciprocals should be used to obtain odds ratios in the opposite direction. Bold-faced figures indicate a difference between treatments with 95 % credible intervals of estimates excluding 1. For abbreviations see Table 2
  2. The results are standardized mean differences (post-treatment depression scores with 95 % confidence intervals) and odds ratios (study discontinuation with 95 % credible intervals) when comparing the column-defined treatments with the row-defined treatments